The DSO Rebound: Why 2026 Is the Most Active Dental M&A Year Since 2022

Bypaulgruensfelder
Becker’s Dental Review May 21, 2026
Read Full Article →
AI-Generated Summary

Dental M&A has rebounded strongly in 2026 after a slowdown driven by elevated capital costs, enhanced due diligence, and unrealistic seller valuations. DSOs are aggressively expanding across specialties — from pediatrics to orthodontics — backed by private equity and strategic investors, with 69% of DSOs surveyed reporting their PE sponsors expect a moderate or significant increase in acquisitions this year. Multiple drivers are converging: 60% of practices reported higher top-line revenue in 2024, an aging dentist population (40%+ of dentists are 55 or older in several states), and rising patient demand. The market is currently high-demand, low-supply, pushing DSOs to apply more scrutiny to deal quality and practice performance metrics. Regulatory headwinds persist — California recently expanded the attorney general’s authority over PE entities operating in dental markets.

Why It Matters

PE-backed dental platforms competing for acquisitions in 2026 face a tighter deal environment with less margin for error on valuation. Groups that pair selective acquisition discipline with strong pre-acquisition performance metrics — and monitor emerging state-level regulatory risk — will be best positioned in the current cycle.

dental DSO M&A private equity dentistry dental acquisitions 2026 DSO expansion dental market consolidation PE-backed dental groups

While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.

Similar Posts

  • Four Forces Disrupting DSO Growth in 2026: PE, Integration, AI, and Diagnostics

    Bypaulgruensfelder

    Four major forces are reshaping DSO growth in 2026: private equity resurging in oral surgery (up 9.1% in PE deals), medical-dental integration expanding through health system partnerships, AI adoption at scale across patient communication and operations, and salivary diagnostics emerging as a clinical frontier. For DSO growth teams and PE investors, this signals where capital and clinical energy are concentrating — and what capabilities will separate market leaders from laggards through 2027.

  • The Attribution Problem Your Board Doesn’t Understand

    Bypaulgruensfelder

    Healthcare marketing attribution is genuinely hard for multi-site groups because patient journeys are long, largely offline, and privacy-constrained—and a budget you can’t defend is a budget that gets cut. Strategy Collective’s Matt Lee argues perfect attribution doesn’t exist, but ‘good enough’ attribution is achievable through four moves: call tracking, redesigned patient intake questions, a blended market-level report, and separating brand demand from generated demand. The bigger fix is reframing the board conversation itself. Instead of asking ‘is marketing working?’, leaders should ask ‘how do we make Market B look like Market A?’—shifting from an unwinnable ROI-proof debate to a comparative, market-level view that drives real reallocation decisions.

  • Q3 2026 AI Trends: What Growth Leaders Need to Track

    Bypaulgruensfelder

    The most useful AI question for growth-stage leaders in Q3 2026 has shifted from what models can do to what results they actually deliver. Summit Partners’ AI and data science team flags five developments to track: the conversation has moved from capability to production results; the binding constraint is rarely the model itself but data, workflow, and integration; agents are evolving from assistants to actors, with trust as the real limiting factor; the underlying economics of AI are being rewritten; and leaders must separate genuine signal from noise while recognizing what work stays human. The throughline is disciplined execution—turning promising pilots into dependable, measurable production systems.

  • PE’s Quieter Playbook: Joint Ventures With Nonprofit Health Systems

    Bypaulgruensfelder

    Private equity firms are increasingly expanding in healthcare through joint ventures with nonprofit health systems rather than outright buyouts, according to a new report from the Private Equity Stakeholder Project. The report finds 21.4% of private equity-owned hospitals are held through joint venture arrangements with nonprofit systems, and the structure now spans hospitals, inpatient rehab, hospice, home health, behavioral health, ambulatory surgery centers and urgent care — likely an undercount, since the tally covers only publicly identifiable arrangements. Case studies include ventures involving Lifepoint Health, Compassus, Ardent Health Services and Ascension. PESP argues these JVs have drawn far less scrutiny than traditional PE buyouts even as they become more common, prompting calls for greater oversight.

  • Why Penn Medicine Is Deploying AI Agents for Patient Intake

    Bypaulgruensfelder

    Penn Medicine is integrating K Health’s AI-powered patient intake agents into its virtual primary care service, testing whether an AI ‘team member’ in the patient-provider relationship improves outcomes. The agents collect symptoms and medical history before a visit and convert them into structured summaries that feed directly into the clinician’s existing workflow — providers start appointments already informed, and patients get routed to the right level of care. The same K Health technology already runs inside virtual care programs at Cedars-Sinai, Mayo Clinic, Mass General Brigham and Hartford HealthCare, with use cases ranging from new-patient acquisition to expanding primary care access. If the pilot succeeds, Penn plans to extend the agents into in-person primary care offices and specialty clinics.

  • Patient Portal Messages Have Surged 153% Since COVID, JAMA Study Finds

    Bypaulgruensfelder

    Patient-authored messages to providers have surged 153% since the COVID-19 pandemic, and a new JAMA study using Epic data finds the increase did not reduce telehealth or in-person visits. The authors conclude that patient messaging functions as an expansion of between-visit care rather than a substitute for it, and that the steady, gradual rise makes the trend likely to persist. Messaging was most common among female patients, patients aged 40 to 64, and those in affluent neighborhoods. The operational cost is significant: the AMA reports inbox overload is now a leading driver of physician burnout, with some physicians spending up to two hours nightly clearing their in-basket, and burnout conservatively costing health systems over $5 billion a year.